Julia Whitman1, Isabel E Allen2, Emily K Bergsland1,3, Insoo Suh4, Thomas A Hope5,6,7. 1. Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California. 2. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California. 3. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. 4. Department of Surgery, University of California San Francisco, San Francisco, California. 5. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu. 6. Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; and. 7. Department of Radiology, San Francisco VA Medical Center, San Francisco, California.
Abstract
Hyperparathyroidism is an endocrine disorder caused by one or more hyperfunctioning parathyroid glands. Current imaging consisting of ultrasound and 99mTc-sestamibi is imprecise, making localization difficult. 18F-fluorocholine (18F-FCH) PET has recently shown promise in presurgical localization of parathyroid adenomas. The primary aim of this study was to summarize the sensitivities and specificities of studies using 18F-FCH PET to localize hyperparathyroidism. A secondary aim was to summarize a subset of studies in which 99mTc-sestamibi scans were also used and to compare the performance of the 2 modalities. Methods: We searched the MEDLINE and EMBASE databases following the PRISMA (Preferred Reporting Items for Systematic Review and Metaanalysis) statement. Quality was assessed using the QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies). Twenty studies were included for quantitative assessment in our metaanalysis. A random-effects model and a hierarchic summary receiver-operating-characteristic model was used to summarize the sensitivity of 18F-FCH PET in detecting abnormal parathyroid adenomas. We used the same methodology to assess sensitivity of 99mTc-sestamibi, as a comparison to 18F-FCH PET. Results: 18F-FCH PET had a high sensitivity, 0.97 (range, 0.96-0.98), for the detection of abnormal parathyroid adenomas. In the subpopulation for which both 18F-FCH and 99mTc-sestamibi were reported, 18F-FCH also had a higher sensitivity, 0.96 (0.94-0.98), than the 0.54 (0.29-0.79) reported for 99mTc-sestamibi (P < 0.001). Conclusion: 18F-FCH PET demonstrates high localization accuracy in patients with hyperparathyroidism. This metaanalysis supports the use of 18F-FCH over 99mTc-sestamibi in patients with hyperparathyroidism.
Hyperparathyroidism is an endocrine disorder caused by one or more hyperfunctioning parathyroid glands. Current imaging consisting of ultrasound and 99mTc-sestamibi is imprecise, making localization difficult. 18F-fluorocholine (18F-FCH) PET has recently shown promise in presurgical localization of parathyroid adenomas. The primary aim of this study was to summarize the sensitivities and specificities of studies using 18F-FCH PET to localize hyperparathyroidism. A secondary aim was to summarize a subset of studies in which 99mTc-sestamibi scans were also used and to compare the performance of the 2 modalities. Methods: We searched the MEDLINE and EMBASE databases following the PRISMA (Preferred Reporting Items for Systematic Review and Metaanalysis) statement. Quality was assessed using the QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies). Twenty studies were included for quantitative assessment in our metaanalysis. A random-effects model and a hierarchic summary receiver-operating-characteristic model was used to summarize the sensitivity of 18F-FCH PET in detecting abnormal parathyroid adenomas. We used the same methodology to assess sensitivity of 99mTc-sestamibi, as a comparison to 18F-FCH PET. Results: 18F-FCH PET had a high sensitivity, 0.97 (range, 0.96-0.98), for the detection of abnormal parathyroid adenomas. In the subpopulation for which both 18F-FCH and 99mTc-sestamibi were reported, 18F-FCH also had a higher sensitivity, 0.96 (0.94-0.98), than the 0.54 (0.29-0.79) reported for 99mTc-sestamibi (P < 0.001). Conclusion: 18F-FCH PET demonstrates high localization accuracy in patients with hyperparathyroidism. This metaanalysis supports the use of 18F-FCH over 99mTc-sestamibi in patients with hyperparathyroidism.
Authors: Amit Mahajan; Lee F Starker; Monica Ghita; Robert Udelsman; James A Brink; Tobias Carling Journal: World J Surg Date: 2012-06 Impact factor: 3.352
Authors: Michael W Yeh; Philip H G Ituarte; Hui Cynthia Zhou; Stacie Nishimoto; In-Lu Amy Liu; Avital Harari; Philip I Haigh; Annette L Adams Journal: J Clin Endocrinol Metab Date: 2013-02-15 Impact factor: 5.958
Authors: Serena Grimaldi; Jacques Young; Peter Kamenicky; Dana Hartl; Marie Terroir; Sophie Leboulleux; Amandine Berdelou; Julien Hadoux; Segolene Hescot; Hervé Remy; Eric Baudin; Martin Schlumberger; Désirée Deandreis Journal: Eur J Nucl Med Mol Imaging Date: 2018-04-22 Impact factor: 9.236
Authors: Diego Alfonso López-Mora; Marina Sizova; Montserrat Estorch; Albert Flotats; Valle Camacho; Alejandro Fernández; Safae Abouzian; Francisco Fuentes-Ocampo; José Ignacio Pérez Garcia; Ana Isabel Chico Ballesteros; Joan Duch; Anna Domènech; Antonio Moral Duarte; Ignasi Carrió Journal: Eur J Nucl Med Mol Imaging Date: 2020-01-09 Impact factor: 9.236
Authors: Abdullah A Alharbi; Fahad M Alshehri; Abdulrahman A Albatly; Bert-Ram Sah; Christoph Schmid; Gerhard F Huber; Martin W Huellner Journal: Mol Imaging Biol Date: 2018-10 Impact factor: 3.488
Authors: Wouter P Kluijfhout; Jesse D Pasternak; Jessica E Gosnell; Wen T Shen; Quan-Yang Duh; Menno R Vriens; Bart de Keizer; Thomas A Hope; Christine M Glastonbury; Miguel H Pampaloni; Insoo Suh Journal: Radiology Date: 2017-01-25 Impact factor: 11.105
Authors: Ismini C Mainta; Marie-Laure Matthey Gié; Frédéric Triponez; Martin A Walter Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-17 Impact factor: 9.236
Authors: Maria P Yavropoulou; Sofia Vlachou; Marina Tsoli; Florentia Fostira; Gregory Kaltsas; Eva Kassi Journal: J Clin Med Date: 2022-04-01 Impact factor: 4.241